RHHBF - Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?

2025-02-10 14:55:00 ET

Summary

• Celldex's lead molecule, Barzolvolimab, showed positive phase 2 data in treating chronic urticaria, despite the company's history of failed molecules and no approved products.
• The market reacted negatively to 2024 data drops, possibly due to high discontinuation rates and adverse events, despite promising clinical results.
• Financially, Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024.
• Given the stock's declining trend and market skepticism, I recommend caution and suggest monitoring the stock further before making investment decisions.

I covered Celldex Therapeutics, Inc. ( CLDX ) twice in the last decade, and both times I lamented the poor performance of the stock and the company. In one of these articles, I presented a list of Celldex’s failures. The list included 7 molecules in a span of 7 years!...

For further details see: